Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hakan Önder

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Breast (Edinburgh, Scotland)|April 4, 2025
Reevaluating prognostic differences in HR+/HER2- Breast Cancer: The unaccounted impact of CDK4/6 inhibitorsArif Hakan Önder
Lancet (London, England)|August 16, 2025
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trialArif Hakan Önder
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Re-Evaluating the Overall Survival Advantage of Segmentectomy: A Missing Perspective on AgeArif Hakan Önder
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2026
Small Cemetery WithinArif Hakan Önder
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Letter to the Editor: On the clinical irrelevance of SUCRA rankings in relapsed small-cell lung cancerArif Hakan Önder
ESMO Open|May 7, 2025
Letter re: Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2Arif Hakan Önder
ESMO Open|May 1, 2025
Letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trialArif Hakan Önder
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2025
Evolving standards in rectal cancer: Are we moving beyond local control?Arif Hakan Önder
Journal of Cancer Policy|July 6, 2025
Memory, merit, and the machinery of silence: Reconstructing integrity in systems that do not discloseArif Hakan Önder
Clinical Lung Cancer|July 13, 2025
Letter to the Editor: "CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression"Arif Hakan Önder
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Breast (Edinburgh, Scotland)|April 4, 2025
Reevaluating prognostic differences in HR+/HER2- Breast Cancer: The unaccounted impact of CDK4/6 inhibitorsArif Hakan Önder
Lancet (London, England)|August 16, 2025
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trialArif Hakan Önder
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Re-Evaluating the Overall Survival Advantage of Segmentectomy: A Missing Perspective on AgeArif Hakan Önder
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2026
Small Cemetery WithinArif Hakan Önder
Lung Cancer (Amsterdam, Netherlands)|November 15, 2025
Letter to the Editor: On the clinical irrelevance of SUCRA rankings in relapsed small-cell lung cancerArif Hakan Önder
ESMO Open|May 7, 2025
Letter re: Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2Arif Hakan Önder
ESMO Open|May 1, 2025
Letter re: The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trialArif Hakan Önder
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2025
Evolving standards in rectal cancer: Are we moving beyond local control?Arif Hakan Önder
Journal of Cancer Policy|July 6, 2025
Memory, merit, and the machinery of silence: Reconstructing integrity in systems that do not discloseArif Hakan Önder
Clinical Lung Cancer|July 13, 2025
Letter to the Editor: "CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression"Arif Hakan Önder
Pageof 6